You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 3
  • 1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum

Citation Tools

Article menu

Download PDFPDF

IGCS meeting abstracts
Plenary sessions
Plenary 1
IGCS19-0523
1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Grisham R, Monk J B, Banerjee S, et al
1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
International Journal of Gynecologic Cancer 2019;29:A1.